MovDisordV3, Main, Exploration, bibRecord, 002225

Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

Identifieur interne : 002225 ( Main/Exploration ); précédent : 002224; suivant : 002226

Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

Auteurs : Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël]

Source :

Movement Disorders [ 0885-3185 ] ; 2009-03-15.

RBID : ISTEX:5B1103AD18D631B83CB2914DC8D246159F83891D

Descripteurs français

Pascal (Inist)
- Etude comparative, Inhibiteur de la monoamine oxidase B, Long terme, Maladie de Parkinson, Modification, Pathologie du système nerveux, Pronostic, Rasagiline, Traitement.

English descriptors

KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Comparative study, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Indans (administration & dosage), Levodopa (therapeutic use), Long term, Longitudinal Studies, MAO‐B inhibitor, Male, Middle Aged, Modification, Monoamine Oxidase Inhibitors (administration & dosage), Monoamine oxidase B inhibitor, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Prognosis, Quality of Life, Rasagiline, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment, Treatment Outcome, disease modification, neuroprotection, rasagiline, treatment.
MESH :
- chemical , administration & dosage : Indans, Monoamine Oxidase Inhibitors.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Longitudinal Studies, Male, Middle Aged, Quality of Life, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.

Abstract

The purpose of this study to compare the long‐term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early‐start group) or placebo for 6 months followed by rasagiline (delayed‐start group) in the TEMPO study. Subjects who chose to participate in an open‐label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5‐year follow‐up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early‐start versus delayed‐start rasagiline group. Although the interaction between treatment and time was significant, values for the early‐start group were better than the delayed‐start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early‐start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD. © 2008 Movement Disorder Society

Url:

https://api.istex.fr/document/5B1103AD18D631B83CB2914DC8D246159F83891D/fulltext/pdf

DOI: 10.1002/mds.22402

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name>
</author>
<author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
</author>
<author><name sortKey="Fitzer Ttas, Cheryl J" sort="Fitzer Ttas, Cheryl J" uniqKey="Fitzer Ttas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5B1103AD18D631B83CB2914DC8D246159F83891D</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22402</idno>
<idno type="url">https://api.istex.fr/document/5B1103AD18D631B83CB2914DC8D246159F83891D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000327</idno>
<idno type="wicri:Area/Istex/Curation">000327</idno>
<idno type="wicri:Area/Istex/Checkpoint">000E27</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hauser R:long:term:outcome</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19086083</idno>
<idno type="wicri:Area/PubMed/Corpus">001F10</idno>
<idno type="wicri:Area/PubMed/Curation">001F10</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001D33</idno>
<idno type="wicri:Area/Ncbi/Merge">002455</idno>
<idno type="wicri:Area/Ncbi/Curation">002455</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002455</idno>
<idno type="wicri:Area/Main/Merge">002A86</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0171575</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F47</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D72</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000E20</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hauser R:long:term:outcome</idno>
<idno type="wicri:Area/Main/Merge">002F17</idno>
<idno type="wicri:Area/Main/Curation">002225</idno>
<idno type="wicri:Area/Main/Exploration">002225</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinsons's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fitzer Ttas, Cheryl J" sort="Fitzer Ttas, Cheryl J" uniqKey="Fitzer Ttas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Teva Pharmaceutical Industries Ltd, Petach Tikva</wicri:regionArea>
<wicri:noRegion>Petach Tikva</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-03-15">2009-03-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="564">564</biblScope>
<biblScope unit="page" to="573">573</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5B1103AD18D631B83CB2914DC8D246159F83891D</idno>
<idno type="DOI">10.1002/mds.22402</idno>
<idno type="ArticleID">MDS22402</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Comparative study</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Indans (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Long term</term>
<term>Longitudinal Studies</term>
<term>MAO‐B inhibitor</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Modification</term>
<term>Monoamine Oxidase Inhibitors (administration & dosage)</term>
<term>Monoamine oxidase B inhibitor</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Prognosis</term>
<term>Quality of Life</term>
<term>Rasagiline</term>
<term>Reproducibility of Results</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>disease modification</term>
<term>neuroprotection</term>
<term>rasagiline</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Quality of Life</term>
<term>Reproducibility of Results</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Etude comparative</term>
<term>Inhibiteur de la monoamine oxidase B</term>
<term>Long terme</term>
<term>Maladie de Parkinson</term>
<term>Modification</term>
<term>Pathologie du   système nerveux</term>
<term>Pronostic</term>
<term>Rasagiline</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this study to compare the long‐term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early‐start group) or placebo for 6 months followed by rasagiline (delayed‐start group) in the TEMPO study. Subjects who chose to participate in an open‐label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5‐year follow‐up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early‐start versus delayed‐start rasagiline group. Although the interaction between treatment and time was significant, values for the early‐start group were better than the delayed‐start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early‐start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Israël</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Floride</li>
<li>Indiana</li>
<li>Pennsylvanie</li>
<li>Texas</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
<name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
<name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name>
<name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
</country>
<country name="Israël"><noRegion><name sortKey="Fitzer Ttas, Cheryl J" sort="Fitzer Ttas, Cheryl J" uniqKey="Fitzer Ttas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002225 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002225 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:5B1103AD18D631B83CB2914DC8D246159F83891D
   |texte=   Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.